Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)

Market Cap	41.73B +34.9%
Revenue (ttm)	5.17B +48.5%
Net Income	2.18B +52.9%
EPS	4.85 +53.1%
Shares Out	450.00M
PE Ratio	19.12
Forward PE	20.92
Dividend	0.80 (0.85%)
Ex-Dividend Date	Sep 10, 2025

Volume	3,317,713
Average Volume	3,436,559
Open	93.72
Previous Close	92.73
Day's Range	92.60 - 94.80
52-Week Range	72.38 - 122.20
Beta	0.39
RSI	32.48
Earnings Date	Apr 23, 2026

About SHA:688578

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China. Its lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC), as well as for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 1,823
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688578

Financial Performance

In 2024, SHA:688578's revenue was 3.56 billion, an increase of 76.29% compared to the previous year's 2.02 billion. Earnings were 1.43 billion, an increase of 121.97%.